Literature DB >> 15650843

The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA ('ecstasy') when housed at high ambient temperature.

Kathryn S Saadat1, Esther O'shea, M Isabel Colado, J Martin Elliott, A Richard Green.   

Abstract

RATIONALE: Administration to rats of a neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) produces an impairment in thermoregulation which is reflected in a prolonged hyperthermic response to a subsequent dose of MDMA given to rats housed at high ambient temperature.
OBJECTIVE: We wished to examine whether the impaired thermoregulation was associated with decreased cerebral 5-HT content produced by the prior neurotoxic dose of MDMA.
METHODS: Rats were injected with drugs decreasing 5-HT function [the tryptophan hydroxlase inhibitor p-chlorophenylalanine (PCPA), and 5-HT receptor antagonists] and rectal temperature was measured after administering MDMA to rats housed at 30 degrees C.
RESULTS: PCPA pretreatment decreased 5-HT and 5-HIAA concentrations in cortex, hippocampus and striatum by >80% and prolonged the hyperthermia induced in rats housed at 30 degrees C by administering MDMA (5 mg/kg i.p.). A similar prolongation of the hyperthermic response to MDMA was seen when rats were pretreated with methysergide (10 mg/kg i.p.) or the 5-HT(1A) antagonist WAY100635 (0.5 mg/kg s.c.).
CONCLUSIONS: Decreasing 5-HT function in diverse ways enhanced the hyperthermic response to MDMA given to rats housed at high ambient temperature. This suggests that loss of 5-HT acting on 5-HT(1A) receptors leads to impaired thermoregulation in rats and suggests that the impairment seen in MDMA pretreated rats housed at high ambient temperature is due to a loss in 5-HT function. These data could have implications for recreational users of MDMA, who may have damaged serotoninergic neurons because of prior heavy or frequent use of the drug, when taking further doses of MDMA in hot environments such as dance clubs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650843     DOI: 10.1007/s00213-004-2106-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  38 in total

1.  Factors influencing the toxicity of sympathomimetic amines to solitary mice.

Authors:  M R A CHANCE
Journal:  J Pharmacol Exp Ther       Date:  1947-03       Impact factor: 4.030

2.  Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: association with altered 5-HT transporter and receptor density.

Authors:  Iain S McGregor; Kelly J Clemens; Geoffrey Van der Plasse; Kong M Li; Glenn E Hunt; Feng Chen; Andrew J Lawrence
Journal:  Neuropsychopharmacology       Date:  2003-04-16       Impact factor: 7.853

Review 3.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

4.  Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")

Authors:  J A Henry; K J Jeffreys; S Dawling
Journal:  Lancet       Date:  1992-08-15       Impact factor: 79.321

5.  Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones.

Authors:  Veronica Sanchez; Esther O'shea; Kathryn S Saadat; J Martin Elliott; M Isabel Colado; A Richard Green
Journal:  J Psychopharmacol       Date:  2004-09       Impact factor: 4.153

6.  Effect of 5-HT depletion by MDMA on hyperthermia and Arc mRNA induction in rat brain.

Authors:  Thomas J R Beveridge; Annis O Mechan; Marie Sprakes; Qi Pei; Tyra S C Zetterstrom; A Richard Green; J Martin Elliott
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

7.  Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA.

Authors:  A Richard Green; Veronica Sanchez; Esther O'Shea; Kathryn S Saadat; J Martin Elliott; M Isabel Colado
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

8.  The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy').

Authors:  E O'Shea; R Granados; B Esteban; M I Colado; A R Green
Journal:  Neuropharmacology       Date:  1998-07       Impact factor: 5.250

9.  Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine.

Authors:  J F Nash; H Y Meltzer; G A Gudelsky
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

10.  The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats.

Authors:  J F Deakin; A R Green
Journal:  Br J Pharmacol       Date:  1978-10       Impact factor: 8.739

View more
  10 in total

1.  Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques.

Authors:  R D Crean; S A Davis; S N Von Huben; C C Lay; S N Katner; M A Taffe
Journal:  Neuroscience       Date:  2006-07-28       Impact factor: 3.590

2.  Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures.

Authors:  A Richard Green; Esther O'Shea; Kathryn S Saadat; J Martin Elliott; M Isabel Colado
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 3.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  Serotonin Depletion Does not Modify the Short-Term Brain Hypometabolism and Hippocampal Neurodegeneration Induced by the Lithium-Pilocarpine Model of Status Epilepticus in Rats.

Authors:  Luis García-García; Ahmed Anis Shiha; Pablo Bascuñana; Javier de Cristóbal; Rubén Fernández de la Rosa; Mercedes Delgado; Miguel A Pozo
Journal:  Cell Mol Neurobiol       Date:  2015-07-25       Impact factor: 5.046

5.  Distribution of temperature changes and neurovascular coupling in rat brain following 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") exposure.

Authors:  Daniel Coman; Basavaraju G Sanganahalli; Lihong Jiang; Fahmeed Hyder; Kevin L Behar
Journal:  NMR Biomed       Date:  2015-08-19       Impact factor: 4.044

6.  Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia.

Authors:  Emily Joy Jaehne; Abdallah Salem; Rodney James Irvine
Journal:  Psychopharmacology (Berl)       Date:  2007-05-27       Impact factor: 4.530

7.  Effects of MDMA on body temperature in humans.

Authors:  Matthias E Liechti
Journal:  Temperature (Austin)       Date:  2014-10-31

8.  Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review.

Authors:  Jan van Amsterdam; Tibor M Brunt; Mimi Pierce; Wim van den Brink
Journal:  Neurotox Res       Date:  2021-09-23       Impact factor: 3.911

9.  Interactions between ethanol and cocaine, amphetamine, or MDMA in the rat: thermoregulatory and locomotor effects.

Authors:  Sami Ben Hamida; Erin Plute; Brigitte Cosquer; Christian Kelche; Byron C Jones; Jean-Christophe Cassel
Journal:  Psychopharmacology (Berl)       Date:  2007-11-27       Impact factor: 4.415

10.  Ethanol-MDMA interactions in rats: the importance of interval between repeated treatments in biobehavioral tolerance and sensitization to the combination.

Authors:  Sami Ben Hamida; Erin Plute; Sonia Bach; Christine Lazarus; Antoine Tracqui; Christian Kelche; Anne Pereira de Vasconcelos; Byron C Jones; Jean-Christophe Cassel
Journal:  Psychopharmacology (Berl)       Date:  2007-03-08       Impact factor: 4.415

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.